How ReWalk Is Capitalizing on Its Big Win
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
ReWalk Robotics Ltd. (NASDAQ: RWLK) shares took a step back on Monday after the firm announced that it would be pricing a registered direct offering for $5 million. This comes after the stock had a phenomenal week when the U.S. Food and Drug Administration (FDA) cleared ReWalk’s ReStore soft exo-suit system.
According to the firm, it has entered into definitive agreements with institutional investors providing for the issuance of approximately 833,334 shares at a purchase price of $6.00 per share in a registered direct offering priced at-the-market.
ReWalk also will issue unregistered warrants to purchase up to approximately 416,667 ordinary shares. The warrants will have a term of 5.5 years, be exercisable immediately following the issuance date and have an exercise price of $6.00 per ordinary share.
Note that this offering is expected to result in gross proceeds of approximately $5 million.
Shares of ReWalk were last seen down about 15% at $5.82, in a 52-week range of $2.46 to $33.75. The consensus price target is $4.00.
Contact [email protected] for any questions or corrections.




